sur Mainz BioMed N.V.
Mainz Biomed Launches Enhanced ColoAlert to Improve Screening Efficiency
Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company, announced significant updates to its ColoAlert product on July 25, 2024. ColoAlert, a test for colorectal cancer (CRC), now features a novel DNA stabilizing buffer that accommodates varying sample volumes. This upgrade reduces the need for retesting, delivering screening outcomes within 2 - 3 days upon laboratory arrival.
The updated test, marketed across Europe and select international locations, uses proprietary methods to analyze cell DNA for tumor markers. Users benefit from an improved collection device, a new tube, and a tube holder, enhancing test usability and reliability.
"Our commitment to preserving DNA samples and optimizing testing procedures underscores our dedication to delivering superior colorectal cancer screening while ensuring convenience for patients," said Tarrin Khairi-Taraki, VP Commercial Operations.
The enhanced ColoAlert product is now available to current laboratory partners and prospective collaborators.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Mainz BioMed N.V.